Receptor Decoy Inhibitor of Anthrax Toxin

炭疽毒素受体诱饵抑制剂

• 批准号: 7363773
• 负责人: MARIANNE MANCHESTER
• 金额: $ 49.65万
• 依托单位: SALK INSTITUTE FOR BIOLOGICAL STUDIES
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7363773
• 关键词: Address; Adverse effects; Affect; Affinity; Animals; Anthrax disease; Antibiotics; Antibodies; Antibody Binding Sites; Antigens; Antitoxins; Bacillus anthracis; Bacillus anthracis spore; Bacteria; Bacterial Typing; Binding; Binding Sites; Bioterrorism; Biothrax; Categories; Cessation of life; Chimeric Proteins; Ciprofloxacin; Class; Collagen Type IV; Complex; Decontamination; Development; Disease; Dissociation; Dominant-Negative Mutation; Drug Kinetics; Edema; Effectiveness; Engineering; Future; Growth; Hour; Immunization; In Vitro; Infection; Intoxication; Laminin; Ligand Binding; Ligands; Mails; Mediating; Monoclonal Antibodies; Mus; Mutation; Numbers; Pathogenesis; Peptides; Physiological; Population; Prevention strategy; Production; Property; Proteins; Rate; Rattus; Reproduction spores; Research; Resistance; Role; Staging; System; Therapeutic; Therapeutic antibodies; Time; Toxin; United States; Vaccines; Virulent; aerosolized; anthrax lethal factor; anthrax toxin; anthrax toxin receptors; base; cost; edema factor; falls; immunogenic; in vivo; inhibitor/antagonist; killings; neutralizing antibody; next generation; prevent; receptor; receptor binding; research study

DESCRIPTION (provided by applicant): The spore-forming bacterium Bacillus anthracis causes anthrax, and is classified as one of six Category A agents considered as major threats as a bioweapon. Because of its pivotal role in disease pathogenesis, a number of strategies to inhibit anthrax toxin are currently under development, including monoclonal antibody- based therapies. However, there is significant concern about the ease with which the bacterium may be engineered to avoid vaccine protection or antitoxin therapy, e.g. by removing antibody-binding sites from the protective antigen (PA) toxin subunit. A next-generation strategy for antitoxin development, one that addresses this limitation, involves the use of a soluble receptor decoy inhibitor (RDI); Presumably PA cannot be engineered to evade cellular receptor recognition and therefore the RDI should be effective even against forms of PA that have been deliberately altered to resist antibody neutralization. We have recently developed an RDI which has many properties desirable in a broadly acting anthrax therapeutic: it binds to the receptor-binding site of PA with an affinity that is on a par with some of the leading therapeutic antibodies (Kd = 0.2nM); it blocks intoxication via both known cellular receptors for anthrax toxin; its dissociation rate from PA is extremely slow (t1/2 complex = 15 hours); it is non-immunogenic; its production is easily scaleable using a bacterial expression system; it can neutralize PA at stoichiometric concentrations and protects rats against toxin killing. This research plan represents a comprehensive strategy for advancing the RDI as a candidate therapy for anthrax. We will characterize and optimize its pharmacokinetic properties by disrupting its interaction with its physiological ligands (collagen IV and laminin), and by exploiting PEGylation and Ig fusion protein approaches. We will also establish if this class of inhibitor is effective at neutralizing antibody-resistant forms of PA, as expected. Moreover, we will establish if this class of inhibitor can prevent disease in mice caused by Sterne spores that express either wild-type or antibody-resistant PA. These experiments will set the stage for future studies aimed at establishing the effectiveness of the RDI in preventing disease caused by highly virulent strains of B. anthracis. We anticipate that the RDI will be a useful adjunct anthrax therapy that could potentially synergize with monoclonal antibodies to treat infections caused by wild-type bacterial strains while at the same time providing a straightforward strategy for dealing with engineered, weaponized bacterial strains. Anthrax represents one of the greatest bioterrorism threats to the citizens of the United States. The aim of the proposed research is to develop a soluble therapeutic that will be effective against common strains of the bacterium that causes anthrax as well as against weaponized bacterial strains.

描述（由申请人提供）：形成孢子的细菌炭疽芽孢杆菌引起炭疽，被列为六种被认为是主要威胁的A类生物武器之一。由于炭疽毒素在疾病发病机制中的关键作用，目前正在开发许多抑制炭疽毒素的策略，包括基于单克隆抗体的治疗。然而，值得关注的是，这种细菌很容易被改造以避免疫苗保护或抗毒素治疗，例如，通过从保护性抗原（PA）毒素亚基中去除抗体结合位点。下一代抗毒素开发策略解决了这一限制，包括使用可溶性受体诱饵抑制剂（RDI）；据推测，PA不能被设计为逃避细胞受体识别，因此RDI即使对故意改变以抵抗抗体中和的PA形式也应该有效。我们最近开发了一种RDI，它具有广泛作用的炭疽治疗所需的许多特性：它与PA的受体结合位点结合，其亲和力与一些领先的治疗性抗体相当（Kd = 0.2nM）；它通过两种已知的炭疽毒素细胞受体阻断中毒；其与PA的解离速率极慢（t1/2配合物= 15小时）；它是非免疫原性的；利用细菌表达系统，它的生产很容易规模化；它可以在化学计量浓度中和PA，并保护大鼠免受毒素杀死。该研究计划代表了推进RDI作为炭疽候选疗法的综合战略。我们将通过破坏其与生理配体（胶原IV和层粘连蛋白）的相互作用，以及利用聚乙二醇化和Ig融合蛋白方法来表征和优化其药代动力学特性。我们还将确定这类抑制剂是否如预期的那样有效地中和抗体抵抗形式的PA。此外，我们将确定这类抑制剂是否可以预防由表达野生型或抗体抗性PA的Sterne孢子引起的小鼠疾病。这些实验将为未来的研究奠定基础，旨在确定RDI在预防高毒力炭疽杆菌菌株引起的疾病方面的有效性。我们预计，RDI将成为一种有用的辅助炭疽治疗方法，可能与单克隆抗体协同作用，治疗由野生型菌株引起的感染，同时为处理工程化、武器化菌株提供一种直接的策略。炭疽是对美国公民最大的生物恐怖主义威胁之一。这项拟议研究的目的是开发一种可溶性治疗药物，既能有效对抗引起炭疽的常见细菌菌株，也能对抗武器化的细菌菌株。